Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.
Int J Med Sci
; 20(6): 737-748, 2023.
Article
Dans Anglais
| MEDLINE | ID: covidwho-2327207
ABSTRACT
Purpose:
The effectiveness of inactivated vaccines against acute respiratory syndrome coronavirus 2 (SARSCoV2), the causative agent of coronavirus disease 2019 (COVID-19), has become a global concern. Hence, the aim of this study was to evaluate vaccine safety and to assess immune responses in individuals with chronic respiratory disease (CRD) following a two-dose vaccination.Methods:
The study cohort included 191 participants (112 adult CRD patients and 79 healthy controls [HCs]) at least 21 (range, 21-159) days after a second vaccination. Frequencies of memory B cells (MBCs) subsets and titers of SARS-CoV-2 neutralizing antibodies (NAbs) and anti-receptor binding domain (RBD) IgG antibodies (Abs) were analyzed.Results:
As compared to the HCs, CRD patients had lower seropositivity rates and titers of both anti-RBD IgG Abs and NAbs, in addition to lower frequencies of RBD-specific MBCs (all, p < 0.05). At 3 months, CRD patients had lower seropositivity rates and titers of anti-RBD IgG Abs than the HCs (p < 0.05). For CoronaVac, the seropositivity rates of both Abs were lower in patients with old pulmonary tuberculosis than HCs. For BBIBP-CorV, the seropositivity rates of CoV-2 NAbs were lower in patients with chronic obstructive pulmonary disease than HCs (all, p < 0.05). Meanwhile, there was no significant difference in overall adverse events between the CRD patients and HCs. Univariate and multivariate analyses identified the time interval following a second vaccination as a risk factor for the production of anti-RBD IgG Abs and CoV-2 NAbs, while the CoronaVac had a positive effect on the titers of both Abs. Female was identified as a protective factor for CoV-2 NAb levels.Conclusion:
Inactivated COVID-19 vaccines were safe and well tolerated by CRD patients but resulted in lower Ab responses and the frequencies of RBD-specific MBCs. Therefore, CRD patients should be prioritized for booster vaccinations.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Vaccins contre la COVID-19
/
COVID-19
Type d'étude:
Étude de cohorte
/
Étude d'étiologie
/
Études expérimentales
/
Étude observationnelle
/
Étude pronostique
Les sujets:
Vaccins
Limites du sujet:
Adulte
/
Femelle
/
Humains
langue:
Anglais
Revue:
Int J Med Sci
Thème du journal:
Médicament
Année:
2023
Type de document:
Article
Pays d'affiliation:
Ijms.78766
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS